399-88-2

Basic information

• Product Name: 3-Fluoro-4-methylpyridine
• Synonyms: 3-FLUORO-4-PICOLINE;3-FLUORO-4-METHYLPYRIDINE;3-FLUORO-4-METHYLPYRIDINE (3-FLUORO-4-PICOLINE);4-METHYL-3-FLUOROPYRIDINE;2-fluo-3-methylpyridine;Pyridine, 3-fluoro-4-methyl-;3-Fluoro-4-methylpyridin
• CAS NO: 399-88-2
• Molecular Formula: C₆H₆FN
• Molecular Weight: 111.12
• EINECS: 1312995-182-4
• Product Categories: Fluorin-contained pyridine series;Pyridine;Pyridines
• Mol File: 399-88-2.mol

Chemical Properties

• Boiling Point: 135,6 C
• Flash Point: 34.3 °C
• Appearance: Colorless to pale yellow/Liquid
• Density: 1.08 g/cm
• Refractive Index: 1,479
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 3.48±0.18(Predicted)
• CAS DataBase Reference: 3-Fluoro-4-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluoro-4-methylpyridine(399-88-2)
• EPA Substance Registry System: 3-Fluoro-4-methylpyridine(399-88-2)

Safety Data

• Hazard Codes: T,Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 1993
• HazardClass: 3
• PackingGroup: Ⅲ
• Hazardous Substances Data: 399-88-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-methylpyridine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
3-Fluoro-4-methylpyridine is utilized as a precursor in the production of agrochemicals, such as pesticides and insecticides, due to its potential to enhance the effectiveness of these compounds in agricultural applications.
Used in Organic Synthesis:
3-Fluoro-4-methylpyridine is employed as a building block in the synthesis of other organic compounds, highlighting its versatility and importance in the field of organic chemistry.
It is crucial to handle and store 3-Fluoro-4-methylpyridine with care, adhering to safety guidelines and regulations, given its low to moderate toxicity and potential health hazards, such as skin and eye irritation, and harmful effects if ingested or inhaled.

Upstream product

• 3430-27-1 3-amino-4-methylpyridine 
• 372-47-4 3-Fluoropyridine 
• 74-88-4 methyl iodide 
• 23056-33-9 2-chloro-4-methyl-5-nitro-pyridine 
• 21901-41-7 2-hydroxy-4-methyl-5-nitropyridine 
• 21901-40-6 2-amino-5-nitro-4-picoline 
• 695-34-1 2-Amino-4-methylpyridine 
• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 21901-18-8 2-hydroxy-4-methyl-3-nitropyridine 
• 6635-86-5 2-amino-4-methyl-3-nitropyridine 

Downstream Products

• 393-53-3 3-fluoroisonicotinic acid 
• 33252-59-4 3-fluoro-4-methylpyridine-N-oxide 
• 343-72-6 ethyl 3-fluoroisonicotinate 
• 312904-99-7 2-cyano-3-fluoro-4-methylpyridine 
• 471909-36-1 3-fluoroisonicotinaldehyde oxime 
• 40273-47-0 3-fluoropyridine-4-carbaldehyde 
• 177600-62-3 C₁₃H₁₀FN 
• 1383377-54-5 1-(4-fluorophenyl)-2-(3-fluoropyridin-4-yl)ethanone 
• 1383376-92-8 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)furo[3,4-b]pyridin-5(7H)-one 
• 1383377-50-1 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-picolinonitrile 
• 1383377-51-2 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine-2,3-dicarbonitrile 
• 1383377-56-7 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine 
• 1383377-58-9 3-fluoro-4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine 1-oxide 
• 1383377-62-5 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione 

Relevant articles and documents

Synthesis of some fluorine-containing pyridinealdoximes of potential use for the treatment of organophosphorus nerve-agent poisoning

Fluoroheterocyclic aldoximes were screened as therapeutic agents for the treatment of anticholinesterase poisoning. 2-Fluoropyridine-3- and -6-aldoxime, and 3-fluoropyridine-2- and -4-aldoxime, were synthesised. Attempts to obtain 3,5,6-trifluoropyridine-2,4-bis(aldoxime) and -2-aldoxime, however, proved unsuccessful. Pentafluorobenzaldoxime was prepared by oximation of pentafluorobenzaldehyde. Acid dissociation constants (pKa) and second-order rate constants (kox-) of the fluorinated pyridinealdoximes towards sarin were measured. 2,3,5,6-Tetrafluoropyridine-4- aldoxime had the best profile: its kox- approached that of the therapeutic oxime P2S (310 vs. 120 l mol-1 min-1), but its higher pKa (9.1 vs. 7.8) fell short of the target figure of 8 required for reactivation of inhibited acetylcholinesterase in vivo. N-alkylation of the fluorinated pyridine-aldoximes may reduce their pK a nearer to 8 and enhance their therapeutic potential. Crown Copyright

PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS

The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group ; and either a) R1 and R2 represent hydrogen or specified substituents, or b) R2, R1 and the -NH- group to which R1 is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines

Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phen

Pyrazinone thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: A is ?wherein Y1and Y2are independently hydrogen, C1-4alkyl, C1-4alkoxy, FuHvC(CH2)0-1O—, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1, C3-7cycloalkyl, thio C1-4alkyl, C1-4sulfinylalkyl, C1-4sulfonylalkyl, halogen cyano, or trifluoromethyl, and wherein b is 0 or 1.

THROMBIN INHIBITORS

Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure: or a pharmaceutically acceptable salt thereof, whereinA is whereinY 1 and Y 2 are independentlyhydrogen,C 1-4 alkyl,C 1-4 alkoxy,F uH v C(CH 2) 0-1 O--, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1,C 3-7 cycloalkyl,thio C 1-4 alkyl,C 1-4 sulfinylalkyl,C 1-4 sulfonylalkyl, halogencyano, ortrifluoromethyl, andwherein b is 0 or 1.